ABSTRACT Thyrotoxicosis may be associated with deterioration in asthma. To determine whether bronchial reactivity to histamine is increased in hyperthyroidism 10 thyrotoxic non-asthmatic patients were assessed before and after treatment of their thyrotoxicosis. No significant change in bronchial reactivity was found after treatment.
control.'24 As bronchial hyperreactivity is an important feature of asthma, we have examined whether the effect of altered thyroid hormone state on asthmatic symptoms can be explained by changes in airway responsiveness to histamine.
Methods
Ten subjects (nine female; age range 30-68, mean 45-4 years) with thyrotoxicosis were studied before and after antithyroid treatment. No patients were taking beta adrenergic blockers. Thyroid stimulating hormone (TSH) receptor antibody concentrations (TRab) were measured by the method of Shering and Peer-Smith. Thyroxine and triiodothyronine were estimated with Amerlex RIA kits (Amersham, UK) and TSH by IRMA with the Sucresep kit (Boots, Celltech, UK).
All subjects had Graves disease associated with raised concentrations of TSH receptor antibodies (mean (95% confidence intervals) 38-3 (302-46-4)), expressed as percentage inhibition of TSH binding (normal range -8% to + 8%). All were biochemically thyrotoxic (and untreated) at initial assessment (thyroxine 226-9 (208 9-2249) nmol/l; normal range 54-142 nmol/l), triiodothyronine 5 4 (4 5-63) nmol/l; normal range 0-8-2-7 nmol/l), TSH undetectable (normal range 0 8-5 45 mU/l)). Patients were rendered euthyroid with thioureylene antithyroid drugs (nine with carbimazole, one with propylthiouracil) and were restudied after a sustained period of euthyroidism (6-14 months after initial treatment). Post-treatment thyroxine was 116-3 (SD 12-2) nmol/l, triiodothyronine 1-6 (0 2) nmol/l, TSH 2-3 (0 7) mU/l). Seven subjects reported breathlessness associated with exercise but none had a history of respiratory disease. Five were cigarette smokers and remained so during the study. Four 8) mg/ml and 9-2 (4.9-17-l) mg/ ml; after treatment they were 9 1 (4-8-17-9) and 5 5 (3-0-10-4) mg/ml (figure).
Discussion
The Although weakness of respiratory muscles has previously been found in thyrotoxicosis,9 this mechanism alone is unlikely to account for the changes in symptoms of asthma. Respiratory muscle weakness could, however, contribute to the dyspnoea that commonly accompanies thyrotoxicosis,8
and it may heighten the degree of breathlessness experienced by a patient with pre-existing airways disease.
Thus, although thyroxine did relate to baseline calibre, bronchial reactivity was not increased in our thyrotoxic subjects and did not change when the euthyroid state was achieved. Our results do not suggest that increased bronchial reactivity explains deterioration in asthma control in thyrotoxicosis, though an alteration in bronchial responsiveness specifically in asthmatic patients cannot be excluded by the results of our study. 
